
BerGenBio Investor Relations Material
Latest events

Q4 2024
BerGenBio

M&A Announcement
2 Jul, 2025

M&A Announcement
2 Jul, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BerGenBio
Access all reports
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.
Key slides for BerGenBio
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
BGBIO
Country
🇳🇴 Norway